Cover Image

Effectiveness and safety analysis of Danggui Shaoyao Powder for the treatment of non-alcoholic fatty liver disease: study protocol for a randomized, double-blind, placebo-controlled clinical trial

Abstract Background The incidence of non-alcoholic fatty liver disease (NAFLD) has been on the rise in recent years, and there are no effective drugs to treat NAFLD; therefore, effective prevention and treatment of NAFLD have become a new challenge. Danggui Shaoyao Powder (DGSY) is a classic prescri...

Full description

Saved in:

Bibliographic Details
Main Authors:	Qian Huang (Author), Ziming An (Author), Xin Xin (Author), Qinmei Sun (Author), Siting Gao (Author), Sheng Lv (Author), Xiao Xu (Author), Shuohui Yang (Author), Fang Lu (Author), Jie Yuan (Author), Yu Zhao (Author), Yiyang Hu (Author), Ping Liu (Author), Qin Feng (Author)
Format:	Book
Published:	BMC, 2023-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Qushi Huayu decoction attenuated hepatic lipid accumulation via JAK2/STAT3/CPT-1A-related fatty acid β-oxidation in mice with non-alcoholic steatohepatitis
by: QinMei Sun, et al.
Published: (2022)

Danggui-Shaoyao-San Improves Gut Microbia Dysbiosis and Hepatic Lipid Homeostasis in Fructose-Fed Rats
by: Jing Yin, et al.
Published: (2021)

Using network pharmacology to explore the mechanism of Danggui-Shaoyao-San in the treatment of diabetic kidney disease
by: Jinfei Yang, et al.
Published: (2022)

A multi-target protective effect of Danggui-Shaoyao-San on the vascular endothelium of atherosclerotic mice
by: Yuemeng Sun, et al.
Published: (2023)

Systems pharmacology-based approach to investigate the mechanisms of Danggui-Shaoyao-san prescription for treatment of Alzheimer's disease
by: Qihui Wu, et al.
Published: (2020)

Danggui Shaoyao San: comprehensive modulation of the microbiota-gut-brain axis for attenuating Alzheimer's disease-related pathology
by: Jiawei He, et al.
Published: (2024)

Danggui Shaoyao San and disassembled prescription: neuroprotective effects via AMPK/mTOR-mediated autophagy in mice
by: Xiaoqing Cheng, et al.
Published: (2024)

Integrated Serum Pharmacochemistry, Metabolomics, and Network Pharmacology to Reveal the Material Basis and Mechanism of Danggui Shaoyao San in the Treatment of Primary Dysmenorrhea
by: Hui Xiong, et al.
Published: (2022)

Preliminary Exploration of Clinical Efficacy and Pharmacological Mechanism of Modified Danggui-Shaoyao San in the Treatment of Depression in Patients with Chronic Kidney Disease
by: Xia M, et al.
Published: (2022)

Danggui-Shaoyao-San (DSS) Ameliorates Cerebral Ischemia-Reperfusion Injury via Activating SIRT1 Signaling and Inhibiting NADPH Oxidases
by: Yunxia Luo, et al.
Published: (2021)

Nigella sativa powder for helicobacter pylori infected patients: a randomized, double-blinded, placebo-controlled clinical trial
by: Hedieh Yousefnejad, et al.
Published: (2023)

The efficacy and safety of Yupingfeng Powder with variation in the treatment of allergic rhinitis: Study protocol for a randomized, double-blind, placebo-controlled trial
by: Pui Kuan Cheong, et al.
Published: (2022)

Efficacy and safety of modified Xiao-Feng Powder in the treatment of chronic urticaria: protocol of a randomized double-blind placebo-controlled study
by: Hing Yu Hung, et al.
Published: (2022)

Effects of enzymatically modified isoquercitrin in supplementary protein powder on athlete body composition: a randomized, placebo-controlled, double-blind trial
by: Naomi Omi, et al.
Published: (2019)

A double-blind placebo needle for acupuncture research
by: Takakura Nobuari, et al.
Published: (2007)

Essential fatty acids for premenstrual syndrome and their effect on prolactin and total cholesterol levels: a randomized, double blind, placebo-controlled study
by: Pinho Neto João S, et al.
Published: (2011)

Plant-derived bioactive compounds regulate the NLRP3 inflammasome to treat NAFLD
by: Qian Huang, et al.
Published: (2022)

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALS-L1023 in Non-Alcoholic Fatty Liver Disease
by: Gi-Ae Kim, et al.
Published: (2023)

The efficacy of sumac (Rhus coriaria L.) powder supplementation in biochemical and anthropometric measurements in overweight or obese patients with non-alcoholic fatty liver disease: A double-blind randomized controlled trial
by: Mohsen Mohit, et al.
Published: (2024)

Cariprazine in therapy of visual hallucinations. Randomized, double-blind placebo-controlled study
by: NA Aliyev, et al.
Published: (2021)

A randomized, double-blind, placebo-controlled trial of safety and efficacy of combined praziquantel and artemether treatment for acute schistosomiasis japonica in China
by: Xun-Ya Hou, et al.
Published: (2008)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Loki zupa in Patients With Chronic Asthma
by: Yubao Lv, et al.
Published: (2018)

The effects of grape seed extract supplementation on cardiovascular risk factors, liver enzymes and hepatic steatosis in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study
by: Parisa Ghanbari, et al.
Published: (2024)

The effect of bromelain in periodontal surgery: a double-blind randomized placebo-controlled trial
by: Hossein Babazade, et al.
Published: (2023)

Randomized, placebo-controlled, double-blind trial of Swedish snus for smoking reduction and cessation
by: Nilsson Robert, et al.
Published: (2011)

Fenofibrate in primary sclerosing cholangitis; a randomized, double‐blind, placebo‐controlled trial
by: Behzad Hatami, et al.
Published: (2022)

A double-blind placebo-controlled evaluation of Vitex agnus castus in premenstrual syndrome
by: M Agajani Delavar, et al.
Published: (2002)

Oral lactase for infantile colic: a randomized double-blind placebo-controlled trial
by: Manish Narang, et al.
Published: (2022)

Effects of Pharmacologic Dose of Resveratrol Supplementation on Oxidative/Antioxidative Status Biomarkers in Nonalcoholic Fatty Liver Disease Patients: A Randomized, Double-Blind, Placebo-Controlled Trial
by: Somayyeh Asghari, et al.
Published: (2018)

Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial
by: Milad Daneshi-Maskooni, et al.
Published: (2019)

Safety, tolerability and pharmacokinetics of WXFL10203614 in healthy Chinese subjects: A randomized, double-blind, placebo-controlled phase Ⅰ study
by: Kai Huang, et al.
Published: (2022)

Vitamin D supplementation for primary dysmenorrhea: a double-blind, randomized, placebo-controlled trial
by: Fatemeh Alsadat Rahnemaei, et al.
Published: (2021)

Double-Blind Placebo-Controlled Treatment Trial of Chlamydia trachomatis Endocervical Infections in Pregnant Women
by: David H. Martin, et al.
Published: (1997)

Mifepristone versus placebo to treat uterine myoma: a double-blind, randomized clinical trial
by: Esteve Carbonell JL, et al.
Published: (2013)

Ifenprodil for the treatment of methamphetamine use disorder: An exploratory, randomized, double‐blind, placebo‐controlled trial
by: Hiroko Kotajima‐Murakami, et al.
Published: (2022)

A double-blind placebo-controlled randomized trial of oral saffron in the treatment of rheumatoid arthritis
by: Maryam Sahebari, et al.
Published: (2021)

Efficacy and Safety of Novel Aspirin Formulations: A Randomized, Double-Blind, Placebo-Controlled Study
by: Rocco Mollace, et al.
Published: (2022)

Efficacy, safety and mechanism of Simiaoyongan decoction in the treatment of carotid atherosclerotic plaque: a randomized, double-blind, placebo-controlled clinical trial protocol
by: QinHua Fan, et al.
Published: (2024)

Assessing the efficacy and safety of Yinqiao powder-maxing Ganshi decoction in the treatment of the major symptoms of mild and moderate COVID-19 by telemedicine-study protocol for a randomized, double-blind, placebo-controlled trial
by: Chi Him Sum, et al.
Published: (2024)

Inhibition of Receptor-Interacting Protein Kinase 1 in Chronic Plaque Psoriasis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
by: Valerie J. Ludbrook, et al.
Published: (2024)